# Clinical Genomics Evidence & Deep Research Synthesis: PROBAND_01
**Patient / Cohort Identifier:** `PROBAND_01` | **Report Date:** October 12, 2026
**Target Audience:** Medical Geneticist · Subspecialty Investigator · Primary Care Physician · Clinical Bioinformatician
**Sequencing Depth & Reference:** Mean Called-Locus Depth **50.1x** (Median **50.0x**) on GRCh38.p14

> [!IMPORTANT]
> **AI-Generated Informational & Research Synthesis — Non-Diagnostic Use Only**
> This dossier is computationally synthesized using local artificial intelligence (AI) models and public genomic databases for exploratory research, variant prioritization, and informational purposes only. It is **not** a clinical diagnostic test, does not establish a medical diagnosis, and requires independent clinical laboratory verification prior to altering medical management.

### Orientation: What We Are Covering
This clinical genomics research dossier evaluates **1407 prioritized variants across 1002 clinical genes** and **41 pharmacogenes (377 screened medications)** for **PROBAND_01** (`PROBAND_01`), backed by **50.1x** mean called-locus sequencing depth. This synthesis separates **Mechanistic Causality** (coding loss-of-function, canonical splice disruption, 3D active-site destabilization) from **Statistical Correlation** (GWAS linkage disequilibrium proxies and common polygenic modifiers), audits **Intra-Gene Cis/Trans Phasing** across multi-variant genes, and provides a **Non-Invasive Biomarker Ground-Truthing & Longitudinal Futures Roadmap**.

### Body

#### 1. Primary Mechanistic & High-Priority Clinical Findings (With Locus Depth, VAF & Confidence)
| Gene | Variant & Coordinate (GRCh38) | Zygosity & Phase | Locus DP & VAF | ClinVar Status | CADD (Phred) / REVEL | AlphaGenome AVI (Phred) & Top Driver | Confidence |
| :--- | :--- | :--- | :---: | :--- | :--- | :--- | :---: |
| **CBLIF** | `c.79+1G>A` (`chr11:59845374`) | Heterozygous (Maternal) | `49x` / `0.47` | **Pathogenic** | 32.0 / — | 33.9 (Splicing) | **0.95** |
| **GJB2** | `p.Met34Thr` (`chr13:20189481`) | Heterozygous (Unphased) | `57x` / `0.63` | **Pathogenic** | 20.9 / 0.70 | 23.6 (Cactus) | **0.99** |
| **VDR** | `c.-1172A>G` (`chr12:47906043`) | Homozygous (N/A) | `49x` / `1.00` | **Likely pathogenic** | 5.4 / — | 2.1 (DNASE-seq) | **0.85** |
| **F5** | `p.Arg534Gln` (`chr1:169549811`) | Heterozygous (Unphased) | `58x` / `0.62` | **drug response** | 27.9 / AM:0.20 | 23.6 (Cactus) | **0.99** |
| **PEX6** | `p.Val788Met` (`chr6:42966044`) | Heterozygous (Unphased) | `48x` / `0.58` | **Conflicting classifications of pathogenicity** | 35.0 / 0.92 | 32.3 (Cactus) | **0.88** |
| **GJB3** | `p.Arg75Cys` (`chr1:34784985`) | Heterozygous (Maternal) | `38x` / `0.37` | **Conflicting classifications of pathogenicity** | 26.2 / 0.94 | 32.4 (AlphaMissense) | **0.88** |
| **SCN4A** | `p.His599Arg` (`chr17:63961242`) | Heterozygous (Unphased) | `56x` / `0.59` | **Conflicting classifications of pathogenicity** | 24.4 / 0.93 | 27.8 (AlphaMissense) | **0.88** |

#### 2. Mechanistic Causality vs. Statistical Correlation Matrix
To prevent clinical over-interpretation of statistical GWAS proxies, cohort findings are stratified across four epistemic tiers:

| Epistemic Class | Count in Cohort | Representative Genes | Mechanistic vs. Statistical Distinction & Clinical Rule |
| :--- | :---: | :--- | :--- |
| **Q1 · Confirmed Mechanistic Causality** | **3** | CBLIF, GJB2, CYP3A5 | **Direct Physical Disruption + Clinical Proof:** Concordant ClinVar P/LP curation backed by high AI functional impact (CADD ≥ 20 / AVI ≥ 20). Eligible for non-invasive clinical surveillance. |
| **Q2 · Cryptic AI-Predicted Disruptors** | **166** | DNAH7, GRIA4, HEXA, PLA2G6, TRAK1, TTN | **Biophysical Disruption Without Clinical Database Entry:** Severe deep-learning predicted splice, chromatin, or 3D folding impact currently VUS/unreviewed in ClinVar. Prioritize for biomarker ground-truthing. |
| **Q3 · Database-Curated / Statistical & PGx Modifiers** | **321** | CNTN1, TTN, VDR, ALDH4A1, ANK3, APOB | **Curated Hypomorphic, PGx & Statistical GWAS Loci:** Includes enzymatic drug-response alleles and statistical population modifiers; must **never** trigger invasive monogenic workups. |
| **Q4 · Protective & Resilience Offsets** | **9** | ADH1C, CCR5, CASP8, MPO, NOS3, CDKN2B | **Risk-Attenuating & Cardioprotective Alleles:** Curated protective modifiers buffering baseline metabolic or vascular pathway susceptibility. |

##### 2.1 High-Priority Cryptic AI Disruptors (AlphaGenome 18-Modality Attribution)
| Gene | Variant & Coordinate | Zygosity & Phase | AVI (Phred) & Percentile | Primary Modality Driver | Top SHAP Attribution Weights (`fi_*`) |
| :--- | :--- | :--- | :---: | :--- | :--- |
| **COL23A1** | `c.675+2T>C` (`chr5:178262215`) | Heterozygous (Unphased) | **26.3** (Top 0.23%) | **Splicing** | Splicing: 59.0%, Cactus 241-Way: 20.3%, PhastCons 470-Way: 12.1% |
| **ELOVL7** | `p.Ser79Tyr` (`chr5:60771922`) | Heterozygous (Maternal) | **31.4** (Top 0.07%) | **AlphaMissense** | AlphaMissense: 48.4%, Cactus 241-Way: 31.5%, PhastCons 470-Way: 13.9% |
| **IGFBP5** | `p.Arg193His` (`chr2:216678221`) | Heterozygous (Unphased) | **26.4** (Top 0.23%) | **AlphaMissense** | AlphaMissense: 39.4%, Cactus 241-Way: 38.9%, PhastCons 470-Way: 14.9% |
| **PTDSS2** | `p.Glu232Gly` (`chr11:488272`) | Heterozygous (Unphased) | **25.8** (Top 0.26%) | **AlphaMissense** | AlphaMissense: 48.7%, Cactus 241-Way: 28.4%, PhastCons 470-Way: 16.9% |
| **NSMCE1** | `p.Cys231Tyr` (`chr16:27225755`) | Heterozygous (Paternal) | **30.6** (Top 0.09%) | **AlphaMissense** | AlphaMissense: 50.2%, Cactus 241-Way: 32.3%, PhastCons 470-Way: 14.0% |
| **BTN3A2** | `c.715+2T>G` (`chr6:26370605`) | Heterozygous (Unphased) | **25.4** (Top 0.29%) | **Splicing** | Splicing: 69.3%, PhastCons 470-Way: 14.6%, CAGE Promoter: 4.1% |

#### 3. Intra-Gene Cis / Trans Phase Auditor & Cross-Pathway Epistasis
Parental and read-backed phasing across all multi-variant genes in **PROBAND_01** resolved **45 Trans Multi-Variant Genes** (variants on opposite parental homologs; 0 confirmed biallelic pathogenic recessive compound-heterozygotes) and **38 Cis Haplotype Genes** (variants co-inherited on the same parental chromosome, leaving the opposite parental homolog completely wild-type).

| Gene | Organ System | Phased Architecture | Variant Count (Mat / Pat) | Max CADD (Phred) | Clinical & Inheritance Interpretation |
| :--- | :--- | :--- | :---: | :---: | :--- |
| **DHRS3** | Heart & Cardiovascular | **TRANS (Biallelic / Compound Het Candidate)** | 2 (1M / 1P) | 28.1 | 1 Maternal + 1 Paternal alleles in trans across DHRS3 |
| **APOB** | Heart & Cardiovascular | **TRANS (Biallelic / Compound Het Candidate)** | 10 (2M / 3P) | 28.0 | 2 Maternal + 3 Paternal alleles in trans across APOB |
| **ANK2** | Multisystem | **TRANS (Biallelic / Compound Het Candidate)** | 3 (1M / 1P) | 27.7 | 1 Maternal + 1 Paternal alleles in trans across ANK2 |
| **CACNA1S** | Heart & Cardiovascular | **TRANS (Biallelic / Compound Het Candidate)** | 12 (4M / 3P) | 26.8 | 4 Maternal + 3 Paternal alleles in trans across CACNA1S |
| **VPS13C** | Multisystem | **TRANS (Biallelic / Compound Het Candidate)** | 3 (1M / 1P) | 25.6 | 1 Maternal + 1 Paternal alleles in trans across VPS13C |
| **MYOM1** | Multisystem | **TRANS (Biallelic / Compound Het Candidate)** | 3 (2M / 1P) | 25.2 | 2 Maternal + 1 Paternal alleles in trans across MYOM1 |
| **TENM4** | Multisystem | **TRANS (Biallelic / Compound Het Candidate)** | 4 (1M / 1P) | 24.3 | 1 Maternal + 1 Paternal alleles in trans across TENM4 |
| **TTN** | Heart & Cardiovascular | **TRANS (Biallelic / Compound Het Candidate)** | 4 (2M / 1P) | 23.4 | 2 Maternal + 1 Paternal alleles in trans across TTN |
| **PLEC** | Heart & Cardiovascular | **TRANS (Biallelic / Compound Het Candidate)** | 3 (1M / 2P) | 23.2 | 1 Maternal + 2 Paternal alleles in trans across PLEC |
| **FLT1** | Multisystem | **TRANS (Biallelic / Compound Het Candidate)** | 2 (1M / 1P) | 22.9 | 1 Maternal + 1 Paternal alleles in trans across FLT1 |

#### 4. Actionable Pharmacogenomic (CPIC / DPWG) Medication Matrix
| Prescribing Action | Screened Drug Count | Key Affected Medications & Causal Pharmacogenes |
| :--- | :---: | :--- |
| **🚫 Avoid / Contraindicated** | **2** | **Combined Oral Contraceptives (Estrogen/Progestin)** (F5), **Hormone Replacement Therapy (Estrogen Hrt)** (F5) |
| **⬇️ Reduce Dose** | **6** | **Celecoxib (Celebrex)** (CYP2C9), **Phenytoin (Dilantin)** (CYP2C9), **Voriconazole** (CYP2C19/NR1I2/POR/ABCB1), **Warfarin (Coumadin)** (CYP2C9), **Fluorouracil** (MTHFR/DPYD/RGS5/SELE/EXO1/UGT1A4/OGG1/XPC/KDR/MSH3/TMEM167A/XRCC4/FLT4/HLA-G/VEGFA/SOD2/ABCB1/PON1/NOS3/WRN/POU5F1B), **Ondansetron** (CYP3A5) |
| **⬆️ Increase Dose / Rapid Clearance** | **2** | **Omeprazole / Pantoprazole / Lansoprazole** (CYP2C19), **Vardenafil** (CYP3A5) |
| **⚠️ Use With Caution** | **124** | **4-Hydroxycyclophosphamide** (CYP3A5), **Belinostat** (UGT1A1), **Beta Blocking Agents** (ADRB2/ADRB1), **Corticosteroids For Systemic Use** (HDAC1), **Hepatitis Vaccines** (IL13), **Irinotecan (Camptosar)** (UGT1A1), **Isoniazid** (NAT2/NR1I2), **Pertussis Vaccines** () |
| **🔍 Monitor** | **8** | **Atazanavir (Reyataz)** (UGT1A1), **Citalopram (Celexa)** (CYP2C19), **Escitalopram (Lexapro)** (CYP2C19), **Flurbiprofen / Ibuprofen** (CYP2C9), **Sertraline (Zoloft)** (CYP2C19), **Erlotinib** (ABCB1), **Glucose** (CRTC2), **Hdl Cholesterol** (CRTC2) |
| **✅ Preferred Alternatives** | **81** | **Antihypertensives** (AGT/CLNK/NAMPT/PTPRD), **Atorvastatin (Lipitor)** (SLCO1B1), **Beta Blocking Agents, Selective** (), **Bisphosphonates** (FDPS), **Clopidogrel (Plavix)** (CYP2C19), **Melatonin Receptor Agonists** (ABCB1), **Rosuvastatin (Crestor)** (SLCO1B1), **Selective Serotonin Reuptake Inhibitors** (AFAP1L1/GABRA6/CAP2/FKBP5/ABCB1/MCPH1/TRPM3/ADRA2A/OR52I2) |

##### 4.1 Allelic Fraction (VAF) Skewing & Mosaicism / Paralog Uncertainty Audit
| Gene | Variant & Coordinate | Locus DP | Observed VAF | Classification | Technical Interpretation |
| :--- | :--- | :---: | :---: | :--- | :--- |
| **PAK3** | `p.Thr247Pro` (`chrX:111163700`) | `15x` | **0.27** | Not reviewed | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |
| **F5** | `p.Thr295Ala` (`chr1:169556715`) | `47x` | **0.34** | Uncertain significance | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |
| **ALKBH3** | `p.Arg70Ter` (`chr11:43884007`) | `50x` | **0.34** | Not reviewed | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |
| **FBXO41** | `p.Glu93Gly` (`chr2:73269353`) | `12x` | **0.17** | Not reviewed | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |
| **TENM2** | `p.Arg1266Gln` (`chr5:168204594`) | `41x` | **0.27** | Not reviewed | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |
| **TCAIM** | `p.Arg217His` (`chr3:44392932`) | `31x` | **0.32** | Uncertain significance | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |

### Conclusions: Diagnostic & Epistemic Decision Calculus

#### Arguments FOR Non-Invasive Surveillance & Genotype-Guided Prescribing
1. **High-Depth Analytical Grounding:** Empirical called-locus coverage (**50.1x** mean depth, **50.0x** median depth) provides high analytical certainty (`0.98`) across SNVs and small indels.
2. **Actionable Pharmacogenomic Safety:** 142 drug-gene interactions across 41 pharmacogenes provide immediate CPIC/DPWG guidance to avoid toxicity and optimize dosing.
3. **Low-Cost Non-Invasive Biomarker Ground-Truthing:** Routine PCP blood panels directly verify physiological homeostasis across the sample's specific prioritized pathways.

#### Arguments AGAINST Over-Intervention (Why Invasive Testing Is Unwarranted)
1. **Heterozygous Recessive Carrier & Modifier Reserve:** Heterozygous variants affecting or potentially affecting one allele in autosomal recessive or modifier genes and uni-allelic *Cis* haplotypes (38 genes) retain one intact wild-type parental copy; invasive diagnostic procedures or restrictive diets are clinically unwarranted.
2. **Statistical GWAS ≠ Monogenic Causality:** Common polygenic modifiers (AF > 1%) reflect population linkage disequilibrium proxies and must never trigger monogenic disease interventions.

### Opportunities: Physiological Ground-Truthing & Longitudinal Futures Roadmap

1. **Primary Care Non-Invasive Blood Panel:** Incorporate the sample-specific non-invasive venous blood panels and preventive evaluations from Section 2.1 of the Clinical Brief into the annual PCP physical.
2. **Cryptic Splice & Regulatory Functional Validation (Quadrant 2):** The **166 Cryptic AI Disruptors** exhibiting high AlphaGenome `AVI` scores driven by splicing or RNA-seq modalities can be inspected via the AlphaGenome Ref vs. Alt Track Predictions view.
3. **Automated Annual Re-Annotation & SHA-256 State Fingerprint:** Baseline SHA-256 callset state fingerprint established (0f7000325413527a…); future annual pipeline runs will automatically report ClinVar/AlphaGenome delta reclassifications against this snapshot.

### Confidence & Uncertainty Assessment
- **Analytical WGS Callset & Phasing Confidence:** **0.98** (Mean Called-Locus Depth `50.1x`, Median `50.0x`).
- **CPIC / DPWG Pharmacogenomic Prescribing Confidence:** **0.95** (41 pharmacogenes, 377 screened drugs).
- **Monogenic Carrier & Surveillance Confidence:** **0.94** (Orthogonal ClinVar, OMIM, CADD, and AlphaGenome agreement).
- **Polygenic / VUS Modifier Penetrance Confidence:** **0.70** (Requires non-invasive biomarker ground-truthing).

## Appendix: Supporting Documentation & Variant Cross-Reference Directory

| Gene | Variant | Coordinates (GRCh38) | ClinVar | dbSNP | OMIM | ClinGen | AlphaGenome Atlas |
| :--- | :--- | :--- | :---: | :---: | :---: | :---: | :---: |
| **CBLIF** | `c.79+1G>A` | `chr11:59845374` | [VCV439755](https://www.ncbi.nlm.nih.gov/clinvar/variation/439755/) | [rs147785187](https://www.ncbi.nlm.nih.gov/snp/rs147785187) | — | [CBLIF](https://search.clinicalgenome.org/kb/genes/CBLIF) | [Atlas](https://alphagenome.deepmind.com/variant/chr11:59845374) |
| **GJB2** | `p.Met34Thr` | `chr13:20189481` | [VCV17000](https://www.ncbi.nlm.nih.gov/clinvar/variation/17000/) | [rs35887622](https://www.ncbi.nlm.nih.gov/snp/rs35887622) | — | [GJB2](https://search.clinicalgenome.org/kb/genes/GJB2) | [Atlas](https://alphagenome.deepmind.com/variant/chr13:20189481) |
| **VDR** | `c.-1172A>G` | `chr12:47906043` | [VCV3336650](https://www.ncbi.nlm.nih.gov/clinvar/variation/3336650/) | [rs4516035](https://www.ncbi.nlm.nih.gov/snp/rs4516035) | — | [VDR](https://search.clinicalgenome.org/kb/genes/VDR) | [Atlas](https://alphagenome.deepmind.com/variant/chr12:47906043) |
| **F5** | `p.Arg534Gln` | `chr1:169549811` | [VCV642](https://www.ncbi.nlm.nih.gov/clinvar/variation/642/) | [rs6025](https://www.ncbi.nlm.nih.gov/snp/rs6025) | — | [F5](https://search.clinicalgenome.org/kb/genes/F5) | [Atlas](https://alphagenome.deepmind.com/variant/chr1:169549811) |
| **PEX6** | `p.Val788Met` | `chr6:42966044` | [VCV556244](https://www.ncbi.nlm.nih.gov/clinvar/variation/556244/) | [rs267608240](https://www.ncbi.nlm.nih.gov/snp/rs267608240) | — | [PEX6](https://search.clinicalgenome.org/kb/genes/PEX6) | [Atlas](https://alphagenome.deepmind.com/variant/chr6:42966044) |
| **GJB3** | `p.Arg75Cys` | `chr1:34784985` | [VCV297191](https://www.ncbi.nlm.nih.gov/clinvar/variation/297191/) | [rs370476720](https://www.ncbi.nlm.nih.gov/snp/rs370476720) | — | [GJB3](https://search.clinicalgenome.org/kb/genes/GJB3) | [Atlas](https://alphagenome.deepmind.com/variant/chr1:34784985) |
| **SCN4A** | `p.His599Arg` | `chr17:63961242` | [VCV324537](https://www.ncbi.nlm.nih.gov/clinvar/variation/324537/) | [rs187401185](https://www.ncbi.nlm.nih.gov/snp/rs187401185) | — | [SCN4A](https://search.clinicalgenome.org/kb/genes/SCN4A) | [Atlas](https://alphagenome.deepmind.com/variant/chr17:63961242) |
